MARK2

Across TCGA pan-cancer cohorts, MARK2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MARK2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where MARK2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MARK2 is over-expressed in tumor, although a few such as COAD and HNSC show the opposite, repressed pattern.

LSCC, CCRCC, and COAD are the cancer types where MARK2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MARK2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	All	III,IV	+0.288	<.001	8	view →
CCRCC	Male	All	+0.104	<.001	7	view →
COAD	Male	All	−0.126	.001	6	view →
LUAD	Male	All	+0.129	<.001	4	view →
HNSC	All	IV	−0.177	.027	1	view →
PDAC	Male	All	−0.136	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MARK2–LSCC

Open the LSCC breakdown →